Core Viewpoint - Northeast Pharmaceutical is focusing on market trends, leveraging its two core sales segments, raw materials and formulations, to achieve significant results and ensure stable performance for the company [1] Raw Material Segment - Northeast Pharmaceutical is a key global supplier of raw materials, enhancing its international market competitiveness, particularly in the EU and Japan/Korea, with market share increasing year by year [2] - The raw material sales company demonstrated strong market capabilities in Q4, with profits exceeding planned targets for two consecutive months in October and November, particularly in November [2] - Key products such as Vitamin C and L-Carnitine exceeded sales targets, while other products like Amantadine and Piracetam also performed well, enhancing the product matrix's competitiveness [2] - The company actively participated in major industry exhibitions to connect with core customer needs and adjust market strategies based on competitor insights [2][3] Formulation Segment - Northeast Pharmaceutical's formulation products rank first in domestic sales, contributing to economic benefits and enhancing brand recognition [4] - The formulation sales company is focusing on maintaining and expanding the market competitiveness of key products, with systematic planning for products like Gut Health and Pain Relief tablets [4] - Efficient execution and collaboration among teams have led to achieving monthly performance targets, providing confidence for year-end goals [4][5] Expansion into New Fields - In Q4, Northeast Pharmaceutical made significant strides in the health sector by launching new products such as health biscuits and advancing the development of additional health-oriented snacks [6] - The company is exploring the beauty sector with functional skincare products, leveraging its pharmaceutical-grade standards in product development [6] - The company aims to optimize its health product matrix and explore comprehensive health services, creating new growth points [6]
东北制药: 核心板块挑大梁 新板块开新局